Ladiratuzumab

Product Specifications

CAS Number

1629760-28-6

Target

Others|||ADC Antibody

Related Pathways

Antibody-drug Conjugate/ADC Related|||Others

Purity

0.982

Bioactivity

LadiratuzumAb (hLIV22) is a humanized monoclonal antibody targeting LIV-1/ZIP6.LadiratuzumAb is a naked antibody to SGN-LIV1A and is capable of synthesizing an antibody-activated molecule coupling (ADC), SGN-LIV1A.LadiratuzumAb can be used for the prevention and treatment of breast cancer.